<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8980409</article-id><article-id pub-id-type="pmc">2074829</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kerr</surname><given-names>D. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>A. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Neoptolemos</surname><given-names>J. P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sherman</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Van-Geene</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stanley</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ferry</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dobbie</surname><given-names>J. W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vincke</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gilbert</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>el Eini</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dombros</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fountzilas</surname><given-names>G.</given-names></name></contrib></contrib-group><aff>CRC Institute for Cancer Studies, University of Birmingham, UK.</aff><pub-date pub-type="ppub"><month>12</month><year>1996</year></pub-date><volume>74</volume><issue>12</issue><fpage>2032</fpage><lpage>2035</lpage><abstract><p>A novel peritoneal carrier solution, Icodextrin 20 (7.5%), has allowed exploration of prolonged, intraperitoneal (i.p.) infusion of the cytotoxic drug 5-fluorouracil (5-FU). A phase I and pharmacokinetic study was performed to determine the toxicities and maximum tolerated dose of prolonged and continuous intraperitoneal 5-FU in patients with peritoneal carcinomatosis. Seventeen patients were entered into this study. Each patient had a Tenckhoff catheter placed into the peritoneal cavity under general anaesthetic. After initial flushing and gradual increase in exchange volumes with Icodextrin 20, 5-FU was administered daily from Monday to Friday, 50% as a bolus in the exchange bag and 50% in an elastomeric infusor device delivering continuous 5-FU to the peritoneal cavity at 2 ml h-1. Treatment was continued for 12 weeks or until intolerable toxicity developed. Abdominal pain and infective peritonitis proved to be the main dose-limiting toxicities. Initial problems with infective peritonitis were overcome by redesign of the delivery system, and it proved possible to deliver 300 mg m-2 5-FU daily (5 days per week) for 12 weeks. Pharmacokinetic studies showed i.p. steady-state 5-FU concentrations (mean 47 500 ng ml-1) that were &#x0003e; 1000-fold higher than systemic venous levels (mean 30 ng ml-1).</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00028-0182.tif" xlink:title="scanned-page" xlink:role="2032" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00028-0183.tif" xlink:title="scanned-page" xlink:role="2033" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00028-0184.tif" xlink:title="scanned-page" xlink:role="2034" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00028-0185.tif" xlink:title="scanned-page" xlink:role="2035" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

